Drug Profile
Opolimogene capmilisbac - Janssen Biotech
Alternative Names: ADU-741; JNJ-64041809; JNJ-809; Opolimogene-capmilisbacLatest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator Aduro BioTech
- Developer Janssen Biotech
- Class Bacteria; Gene therapies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Gene transference; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
- 05 Oct 2020 Aduro Biotech has been merged with Chinook Therapeutics to form Chinook Therapeutics
- 31 May 2019 Interim adverse events, immunogencity and efficacy data from a phase I trial in prostate cancer were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)